Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Advanced Medical Solutions Group's Intrinsic Value: Projected FCF or its related term are showing as below:
CHIX:AMSl'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.11 Med: 1.65 Max: 2.24
Current: 1.43
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Advanced Medical Solutions Group was 2.24. The lowest was 1.11. And the median was 1.65.
CHIX:AMSl's Price-to-Projected-FCF is ranked better than 52.68% of 410
companies
in the Medical Devices & Instruments industry
Industry Median: 1.5
vs CHIX:AMSl: 1.43
Advanced Medical Solutions Group (CHIX:AMSl) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Advanced Medical Solutions Group's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
2.8175
/
1.9717025283417
=
1.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group Intrinsic Value: Projected FCF Related Terms
Advanced Medical Solutions Group Intrinsic Value: Projected FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group Intrinsic Value: Projected FCF Chart
CHIX:AMSL vs ISRG, BDX, MDLN: Intrinsic Value: Projected FCF Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's Price-to-Projected-FCF falls into.
Advanced Medical Solutions Group Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of £1.97 mean?
Advanced Medical Solutions Group (CHIX:AMSL) has a Intrinsic Value: Projected FCF of £1.97 as of Aug. 26, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Advanced Medical Solutions Group and its competitors. According to the industry distribution chart, Advanced Medical Solutions Group ranks #194 out of 410 companies in the Medical Devices & Instruments industry, placing it in the top 47.3%.
Is Advanced Medical Solutions Group's Intrinsic Value: Projected FCF too high?
Advanced Medical Solutions Group's current Intrinsic Value: Projected FCF is £1.97. Based on the distribution chart, Advanced Medical Solutions Group ranks #194 out of 410 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Advanced Medical Solutions Group has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Intrinsic Value: Projected FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #194 out of 410 companies for Intrinsic Value: Projected FCF. This puts Advanced Medical Solutions Group in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.50, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Advanced Medical Solutions Group and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current Intrinsic Value: Projected FCF is £1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.75, compared to a current price of £2.82 — trading 24.9% below its estimated fair value. The current Intrinsic Value: Projected FCF is £1.97. Advanced Medical Solutions Group's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current Intrinsic Value: Projected FCF is £1.97 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.82 is trading 24.9% below its estimated GF Value™ of £3.75.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
Intrinsic Value: Projected FCF: £1.97
GF Value™: £3.75 vs. price of £2.82 (24.9% below fair value)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
77GF Score
Get the complete analysis for CHIX:AMSL
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 
